WO2021241846A1 - Procédé de prévention et de traitement contre des virus utilisant une lumière bleue - Google Patents

Procédé de prévention et de traitement contre des virus utilisant une lumière bleue Download PDF

Info

Publication number
WO2021241846A1
WO2021241846A1 PCT/KR2021/001529 KR2021001529W WO2021241846A1 WO 2021241846 A1 WO2021241846 A1 WO 2021241846A1 KR 2021001529 W KR2021001529 W KR 2021001529W WO 2021241846 A1 WO2021241846 A1 WO 2021241846A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
blue light
cells
hours
sars
Prior art date
Application number
PCT/KR2021/001529
Other languages
English (en)
Korean (ko)
Inventor
정환정
Original Assignee
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200171948A external-priority patent/KR20210147847A/ko
Application filed by 전북대학교산학협력단 filed Critical 전북대학교산학협력단
Publication of WO2021241846A1 publication Critical patent/WO2021241846A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K13/00—Devices for grooming or caring of animals, e.g. curry-combs; Fetlock rings; Tail-holders; Devices for preventing crib-biting; Washing devices; Protection against weather conditions or insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0604—Lungs and/or airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0606—Mouth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Definitions

  • the present invention relates to a method for preventing and treating viruses using blue light.
  • Viruses have DNA or RNA as their genome and are surrounded by proteins. Viruses cannot reproduce independently, replicate in host cells, and multiply through intercellular infection. Virtually all living things, such as animals, plants, and bacteria, each have a virus that infects them, which causes various diseases such as AIDS and the flu. Diseases caused by viruses typically include acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus, hepatitis or liver cancer caused by hepatitis virus, skin diseases caused by herpesvirus, tumors, and MERS virus (MERS virus). ) caused by respiratory diseases. Methods of treating viruses include delaying or blocking the infection of the virus by damaging or killing the virus-infected host cells.
  • AIDS acquired immunodeficiency syndrome
  • MERS virus MERS virus
  • Corona virus is one of the three major viruses that cause colds in humans along with adenovirus and rhinovirus, and is an RNA virus with a gene size of 27 to 32 kb that can infect humans through various routes.
  • the surface of the virus particle protrudes like a protrusion, and this shape resembles a crown, so it was named after the Latin word “corona” meaning crown. It accounts for 10 to 30% of adult colds that occur mainly in the cold winter, and the main symptom is a nasal cold accompanied by a headache, sore throat, or cough. Since the coronavirus was first discovered in chickens in the 1930s, it has been found in animals such as dogs, pigs, and birds, and in humans in the 1960s.
  • Corona virus has been found in both animals and humans, and as the area of human activity expands, the virus that was prevalent only among animals causes genetic mutations in order to survive and is passed on to humans. Examples include SARS (bats and civets), MERS (bats and camels), and COVID-19 (probably bats).
  • SARS baths and civets
  • MERS baths and camels
  • COVID-19 probably bats.
  • the coronaviruses discovered so far are classified into four genera: Alpha, Beta, Gamma, and Delta.
  • alpha is further divided into types 1a and 1b
  • beta is divided into types 2a, 2b, 2c, and 2d. Of these, alpha and beta infect humans and animals, and gamma and delta infect animals.
  • coronaviruses There are a total of 7 types of coronaviruses that have been identified so far, including HCoV 229E ⁇ HCoV NL63 ⁇ HCoV OC43 ⁇ HCoV HKU1 ⁇ SARS-CoV ⁇ MERS-CoV ⁇ SARS-CoV-2. Of these, four (229E, OC43, NL63, and HKU1) caused only mild symptoms similar to colds. However, SARS (severe acute respiratory syndrome), MERS (MERS-CoV), and coronavirus infection-19 (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) It can cause disease and cause many deaths.
  • SARS severe acute respiratory syndrome
  • MERS MERS
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • Coronavirus Disease 2019 is a new type of coronavirus (SARS-CoV-2) that first emerged in Wuhan, China in December 2019 and has spread throughout China and around the world.
  • SARS-CoV-2 coronavirus
  • the COVID-19 virus has a very high transmission rate and is particularly highly contagious. After being infected with the COVID-19 virus, after an incubation period of about 2 to 14 days (estimated), respiratory symptoms such as fever (37.5 degrees), cough or shortness of breath, and pneumonia appear as the main symptoms, but asymptomatic infections are not uncommon.
  • viruses that invade the respiratory system are known to invade the respiratory system in a similar way, and depending on the characteristics of the virus, it is highly contagious because of its fast dissemination power, or it is high in invasiveness to the host by quickly killing host cells. looks like A common invasive route, etc., enters the mucosal epithelial cells in the respiratory tract via droplets or airflow, and redness, ulceration, and secretion of the pharyngeal mucosa are found.
  • Complications include bronchitis, pneumonia, and sepsis in the elderly or patients with underlying diseases with weakened immunity. Therefore, there is a need for a treatment that reduces the inflammatory response caused by viral infection and inhibits viral activity.
  • the present inventors did not kill the host cell, reduce the inflammatory response, and as a result of studying a method for inhibiting growth or killing an infected virus, when irradiated with blue light, the death rate and inflammatory response of the host cell are reduced while reducing the infection By confirming that it is possible to inhibit the proliferation of viruses, the present invention is submitted with this content.
  • an object of the present invention is to provide a light therapy device for treating or preventing viruses, including an LED or a laser light source in a blue region.
  • the present invention may provide an apparatus for light therapy for treating or preventing a virus, including an LED or a laser light source in a blue region.
  • the blue region may be 400 nm to 500 nm.
  • the LED or laser light source may be irradiated with an irradiation amount of 1.0 to 20 J/cm 2 .
  • the virus may be a virus causing respiratory diseases.
  • the present invention may provide a method of treating a virus comprising; irradiating the above-described device for phototherapy to animals other than humans.
  • the device for phototherapy may be irradiated to any one site selected from the group consisting of the whole body, lungs, airways, nasal mucosa, and oral mucosa of an animal other than a human infected with a virus.
  • the blue region may be 400 nm to 500 nm.
  • the LED or laser light source may be irradiated with an irradiation amount of 1.0 to 20 J/cm 2 .
  • the virus may be a virus causing respiratory diseases.
  • the blue light of the present invention does not kill the virus-infected host cell, suppresses its inflammatory response, and has the effect of inhibiting the growth and killing of the infected virus.
  • 3 is a result of cell viability 24 hours and 48 hours after irradiating the blue light of the present invention to Vero E6 cells.
  • 5 is a result of measuring the cell viability and intracellular virus expression level 24 hours after irradiating the blue light of the present invention to Vero E6 cells infected with SARS-CoV2 virus.
  • Figure 6 is the result of irradiating the blue light of the present invention to Vero E6 cells infected with SARS-CoV2 virus, and then extracting vRNA from the supernatant after 24 hours (left) and 72 hours (right), and measuring its quantification cycle (Cq) value. .
  • Figure 8 shows the blue light of the present invention at 10 J/m 2 SARS-CoV2 virus-infected Vero E6 cells were irradiated once with overlay media containing 0.6% agarose, and the plaques and uninfected cells generated 72 hours later. This is the result of measuring the number of unstained plaques by staining.
  • Figure 9 shows the results of measuring the titer of the virus by irradiating the blue light of the present invention at 10 J/m 2 to MDCK cells infected with H1N1 virus twice, then extracting vRNA from the supernatant after 72 hours, calculating its (Ct) value. am.
  • Viruses that invade the respiratory tract are highly contagious because they spread quickly.
  • the mortality rate increases due to complications such as bronchitis, pneumonia, and sepsis. Therefore, there is a need for a treatment that reduces the inflammatory response caused by viral infection and inhibits viral activity.
  • the present inventors did not die in the host cell, reduce the inflammatory response, and as a result of studying a method for inhibiting or killing the infected virus, when irradiated with blue light, the death rate of the host cell does not decrease, and the inflammatory response is It was confirmed that it reduces, inhibits the growth of, and kills the infected virus, and completed the present invention.
  • the present invention may provide an apparatus for light therapy for treating or preventing a virus, including an LED or a laser light source in a blue region.
  • plaque staining with uninfected cells showed that the number of plaques was statistically higher than that of the control group. was significantly reduced by about 80% or more (FIG. 7). As described above, it was confirmed that the blue light energy level can affect virus inactivation without affecting apoptosis in cells infected with SARS-CoV2 virus.
  • the virus After exposing blue light ⁇ J to MDCK cells infected with H1N1 virus for 30 minutes each at 0 hpi (post-infection hour) and 24 hpi time zones, the virus was allowed to grow for 72 hours, and the supernatant was recovered to determine the Ct value of vRNA. was calculated to determine the virus titer. As a result of the measurement, the virus history was statistically decreased in the control group after one or two blue light irradiation. Through this, it was confirmed that the blue light energy level can affect the virus inactivation in H1N1 virus-infected cells.
  • the blue region may be 400 nm to 500 nm. Preferably, it may be 425 to 475 nm, and more preferably, 450 nm.
  • the LED or laser light source may be irradiated with an irradiation amount of 1.0 to 20 J/cm 2 .
  • the virus may be a virus causing respiratory diseases, preferably adenovirus, influenza virus, parainfluenza virus, PIV, respiratory syncytial virus (RSV), bocavirus ( Human bocavirus, hBoV), metapneumovirus (human metapneumovirus, hMPV), may be any one selected from the group consisting of rhinovirus (rhinovirus) and coronavirus (coronavirus), more preferably corona virus or influenza virus. .
  • the coronavirus is a group consisting of SARS (SARS-CoV, severe acute respiratory syndrome), MERS (MERS-CoV, Middle East respiratory syndrome) and coronavirus infection-19 (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) It may be any one selected from, and more preferably, coronavirus infection-19 (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2).
  • influenza virus may be influenza virus type A, influenza virus type B, influenza type C, influenza virus type D, togotovirus, quaranza virus and salmon anemia virus, preferably influenza virus type A, more preferably may be N1H1.
  • the present invention may provide a method of treating a virus comprising the step of irradiating the above-described device for phototherapy to animals other than humans.
  • the device for phototherapy may be irradiated to any one site selected from the group consisting of the whole body, lungs, airways, nasal mucosa, and oral mucosa of an animal other than a human infected with a virus.
  • light with a wavelength of 400 nm has a penetration depth of 1 mm or less
  • light with a wavelength of 514 nm has a penetration depth of 0.5 to 2 mm
  • light with a wavelength of 630 nm has a penetration depth of 1 to 6 mm
  • 700 to 900 nm Wavelengths of light can penetrate deeper.
  • the light source of the present invention can penetrate the skin of 1 mm to 2 mm, and when irradiated to the whole body, there is an effect of treating viruses floating in microvessels existing in the skin.
  • the blue region may be 400 nm to 500 nm. Preferably, it may be 425 to 475 nm, and more preferably, 450 nm.
  • the LED or laser light source may be irradiated with an irradiation amount of 1.0 to 20 J/cm 2 .
  • the virus may be a virus causing respiratory diseases, preferably adenovirus, influenza virus, parainfluenza virus (PIV), RS virus (respiratory syncytial virus, RSV), rhinovirus ( rhinovirus) and coronavirus (coronavirus) may be any one selected from the group consisting of, and more preferably may be a corona virus.
  • the coronavirus is a group consisting of SARS (SARS-CoV, severe acute respiratory syndrome), MERS (MERS-CoV, Middle East respiratory syndrome) and coronavirus infection-19 (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) It may be any one selected from, and more preferably, coronavirus infection-19 (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2).
  • CCD-1131Sk and CCD-18Co cells were cultured in a 96-well plate at a concentration of 5 x 10 3 , replaced with a medium without fetal bovine serum, and irradiated with 5, 10, 15 J/cm 2 of 450 nm blue light, After 48 hours, 10 ⁇ l MTT (5 mg/ml) was treated and the viability was measured by the MTT method.
  • CCD-1131Sk and CCD-18Co cells were irradiated with blue light at 5, 10, 15 J/cm 2 for 48 hours and then incubated for 48 hours followed by MTT at a concentration of 5 mg/ml. Each ⁇ l was put into 96 wells and incubated for 4 hours. After the culture was completed, the culture medium was removed, and 100 ⁇ l of 2-propanol was added per well to dissolve formazan MTT, and absorbance was measured at 570 nm with an ELISA reader to compare with the control group. No morphological changes were observed in human skin cell lines and colon fibroblasts after blue light energy irradiation (FIG. 1).
  • CT-26 cells were recovered and 7M urea, 2M Thiourea, 4%(w/v) 3-[(3-cholamidopropy) ) dimethyammonio]-1-propanesulfonate (CHAPS), 1% (w/v) dithiothreitol (DTT), 2% (v/v) pharmalyte, and 1 mM benzamidine were mixed with a 2DE lysis solution. Then, for protein extraction, vortexing was performed for 1 hour, centrifugation was performed at 15° C.
  • IPG strips are reswelling composed of 7M urea, 2M thiourea, 2% 3-[(3-cholamidopropy)dimethyammonio]-1-propanesulfonate (CHAPS), 1% dithiothreitol (DTT), and 1% pharmalyte. The solution was reswelled at room temperature for 12 to 16 hours.
  • IPG Strips were incubated with equilibration buffer (50mM Tris-Cl, pH6.8, 6M urea, 2% SDS, 30% glycerol) containing 1% DTT for 10 minutes, and immediately after 2.5% Incubation was continued for 10 minutes with equilibration buffer containing iodoacetamide.
  • equilibration buffer 50mM Tris-Cl, pH6.8, 6M urea, 2% SDS, 30% glycerol
  • Quantitative analysis for confirming the expression change of protein spots from the scanned image was performed using PDQuest software (version 7.0, BioRad). The quantity of each spot was normalized to the intensity of total valid sopts, and protein spots showing a significant change in expression more than double that of the control group were selected. After identifying spots by performing two-dimensional electrophoresis, TCTP, LASP1, Enol 1, and PLS3 expression in actual CT-26 cells were reconfirmed by Western blot based on the analyzed results.
  • the primary antibody was reacted with anti-TCTP (cell signaling), anti-LASP1 (cell signaling), anti-Enol 1 (cell signaling), anti-PLS3 (Santacruz), and anti-GAPDH (cell signaling), It was reacted with a secondary antibody bound to horseradish peroxidase. Thereafter, the ECL kit (Millipore, USA) was treated according to the manufacturer's method to induce a developmental reaction. As a result, it was confirmed that blue light did not affect apoptosis and suppressed the expression of proteins (TCTP, LASP1, Enol 1, PLS3) related to inhibition of cell mobility and invasiveness ( FIG. 4 ).
  • the expression of the DNA or mRNA level was also affected in the expression of the protein. Therefore, it can be considered that an energy level of less than 20 J/cm 2 of blue light does not affect apoptosis in virus-infected cells and can affect cell proliferation, inflammatory response, and protein expression such as kinases in a direction that is suppressed. .
  • the decrease in protein expression after blue light irradiation is considered to be one of the important mechanisms in explaining the mechanism by which virus proliferation is inhibited. It is judged that it can cause the result of inhibition of proliferation and inactivation of function by being inhibited.
  • SARS-CoV2 was confirmed by the Korea Centers for Disease Control and Prevention, and all experimental procedures were conducted in a domestic biosafety level 3 research facility (BL3). After culturing the monkey kidney cell line Vero E6 cells in DMEM medium supplemented with 10% fetal bovine serum, when 70-80% confluence is achieved, SARS-CoV2 is infected and periodically cytopathic effect (CPE) was observed. When cell mutations were clearly observed, the culture medium was collected, and the supernatant was filtered with a 0.45 ⁇ m filter using a centrifuge, then divided and stored at -80 °C. For quantification of SARS-CoV2 virus, the infectious virus titer was expressed as 50% tissue culture infectious dose (TCID50).
  • TCID50 tissue culture infectious dose
  • Virus RNA was extracted according to the provided method and confirmed by RT-PCR. After quantifying and diluting the extracted RNA, qRT-PCR was performed using a target specific primer.
  • RNA 1 ⁇ g of total RNA was mixed with 2 ⁇ l 5X RT buffer, 0.5 ⁇ l RT Enzyme Mix, 0.5 ⁇ l primer Mix, and Nuclease-free water according to the manual of the ReverTra Ace TM qPCR RT kit in a total volume of 10 ⁇ l at 37 °C for 15 minutes. , after 5 min reaction at 98 °C, react at 4 °C to synthesize cDNA.
  • RNA from intracellular or cell culture medium was extracted using the AccuPrep Viral RNA Extraction Kit (K-3033, Bioneer, Korea) provided by the manufacturer. Separated according to the method.
  • Cq quantification cycle
  • the cell supernatant was recovered 24 hours after irradiating 10J of blue light once or twice to measure the number of vRNA copies. After irradiation with blue light once or twice, the number of vRNA copies was statistically significantly reduced by about 50% or more compared to the control group (FIG. 7).
  • Plaque reduction assay is a general method for quantifying and viewing viral infection, and was performed to check whether the intracellular virus suppression effect was observed as the number of vRNA copies decreased after BLED irradiation. Plaque shows host cells damaged by virus infection distinct from surrounding normal cells. When stained with vital dye, normal cells around the plaque are stained, but lesion cells infected with SARS-CoV-2 virus are colorless because the pigment is released. have white spots According to the theory that one infectious virus particle forms a single plaque, plaque was measured using overlay media after SARS-CoV-2 virus infection. Overlay media supplies nutrients and makes a gel-like medium to prevent the virus propagated in the first infected cells from spreading through the medium and infecting surrounding cells.
  • the plaques generated 72 hours after irradiation with BLED 10J in cells infected with SARS-CoV-2 virus were reduced by more than 80% compared to the control group (FIG. 8).
  • the blue light energy level can affect virus inactivation without affecting apoptosis in cells infected with SARS-CoV2 virus.
  • the Mardin-Dardy canine kidney (MDCK) cell line is DMEM (Dulbecco's Modified Eagle's Medium) supplemented with penicillin (5 units/mL) / streptomysin (5 ⁇ g/mL) and 10% fetal bovine serum (Gibco, USA): Gibco, USA) was used as a basal medium, maintaining a 5% CO2 concentration, and cultured at 37°C in a CO2 incubator (Thermo Forma, USA).
  • the antiviral activity test of H1N1 against LED-blue light exposure was performed twice in a 12-well plate in MDCK cells, which are host cells.
  • virus growth media DMEM 0 + 1 ⁇ g/mL TPCK-treated trypsin + 1% P/S
  • DMEM 0 + 1 ⁇ g/mL TPCK-treated trypsin + 1% P/S was added, and at 35 ° C, 5% CO 2 condition cultured.
  • the Blue-LED generator was put together in the CO 2 incubator, and the Blue-LED test group was exposed for 30 minutes at 0 hpi (post-infection hour) and 24 hpi time zones, respectively.
  • the negative control was performed under the same conditions as the test group after blocking blue light using aluminum foil.
  • H1N1_PA_For 5 ⁇ -CGG TCC AAA TTC CTG CTG-3 ⁇ and H1N1_PA_Rev: 5 ⁇ -CAT TGG GTT CCT TCC ATC CA- 3 ⁇
  • a reaction solution containing TB green ® Premix Ex Taq TM (Takara, Cat# RR420). Reaction conditions were 95°C 30 seconds (1 time), 95°C 5 seconds, 55°C 10 seconds, 72°C 20 seconds (45 times), and the virus titer was measured using Thermal Cycler Dice ® Real Time System III (Takara, TP950). measured.
  • a standard curve was prepared by converting the Ct values obtained by performing plaque assay and RT-qPCR analysis by serially diluting H1N1 into PFU/mL units.
  • the slope of the standard curve prepared by plotting the Ct values obtained by step-dilution was -4.065
  • the y-intercept was 45.65
  • R 2 was 0.991.
  • the detection limit of H1N1 was set to a Ct value of 35.
  • the H1N1 virus concentration was calculated and compared in non-LED and blue-LED. As a result, the H1N1 concentration in blue-LED was shown to have the effect of reducing 3.38 times at the level of the 12-well plate. was confirmed (FIG. 9).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un appareil de photothérapie qui utilise une DEL ou une source lumineuse laser pour irradier le système respiratoire et similaire d'animaux par de la lumière dans la région bleue pour ainsi inhiber la croissance ou pour tuer des virus infiltrant le système respiratoire et similaire.
PCT/KR2021/001529 2020-05-29 2021-02-05 Procédé de prévention et de traitement contre des virus utilisant une lumière bleue WO2021241846A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20200065064 2020-05-29
KR10-2020-0065064 2020-05-29
KR10-2020-0171948 2020-12-10
KR1020200171948A KR20210147847A (ko) 2020-05-29 2020-12-10 청색광을 이용한 바이러스를 예방 및 치료하는 방법

Publications (1)

Publication Number Publication Date
WO2021241846A1 true WO2021241846A1 (fr) 2021-12-02

Family

ID=78744985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/001529 WO2021241846A1 (fr) 2020-05-29 2021-02-05 Procédé de prévention et de traitement contre des virus utilisant une lumière bleue

Country Status (2)

Country Link
KR (1) KR20220158661A (fr)
WO (1) WO2021241846A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1457893A (zh) * 2003-04-25 2003-11-26 周明非 雾化式上呼吸道病毒灭活仪
KR101668561B1 (ko) * 2015-07-13 2016-10-21 원광대학교산학협력단 녹색형광단백질을 발현하는 유전자 및 로즈 벵갈을 이용한 암 질환의 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
WO2017031367A1 (fr) * 2015-08-18 2017-02-23 Aspyrian Therapeutics, Inc. Compositions, combinaisons et procédés associés pour photoimmunothérapie
US20170281966A1 (en) * 2016-04-01 2017-10-05 Mohamed A Basiony Device to Kill Micro-Organisms Inside the Respiratory Tract
KR20180067499A (ko) * 2015-07-14 2018-06-20 비타빔 엘티디. 위생, 소독 및 멸균을 위한 방법 및 장치

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1457893A (zh) * 2003-04-25 2003-11-26 周明非 雾化式上呼吸道病毒灭活仪
KR101668561B1 (ko) * 2015-07-13 2016-10-21 원광대학교산학협력단 녹색형광단백질을 발현하는 유전자 및 로즈 벵갈을 이용한 암 질환의 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
KR20180067499A (ko) * 2015-07-14 2018-06-20 비타빔 엘티디. 위생, 소독 및 멸균을 위한 방법 및 장치
WO2017031367A1 (fr) * 2015-08-18 2017-02-23 Aspyrian Therapeutics, Inc. Compositions, combinaisons et procédés associés pour photoimmunothérapie
US20170281966A1 (en) * 2016-04-01 2017-10-05 Mohamed A Basiony Device to Kill Micro-Organisms Inside the Respiratory Tract

Also Published As

Publication number Publication date
KR20220158661A (ko) 2022-12-01

Similar Documents

Publication Publication Date Title
Petti et al. The controversial natural history of oral herpes simplex virus type 1 infection
El-Sayed et al. Coronaviruses in humans and animals: the role of bats in viral evolution
Tabibzadeh et al. Evolutionary study of COVID‐19, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) as an emerging coronavirus: Phylogenetic analysis and literature review
Rosato et al. Neuronal interferon signaling is required for protection against herpes simplex virus replication and pathogenesis
Pauli et al. Orthopox viruses: infections in humans
Kropski et al. Right place, right time: the evolving role of herpesvirus infection as a “second hit” in idiopathic pulmonary fibrosis
Rehman et al. Pathobiology of Avian avulavirus 1: special focus on waterfowl
Zhang et al. Emerging natural recombinant Marek's disease virus between vaccine and virulence strains and their pathogenicity
Ren et al. Establishment of inflammatory model induced by Pseudorabies virus infection in mice
WO2017200192A1 (fr) Composition d'additif d'aliments pour amimaux à activité antivirale
WO2021241846A1 (fr) Procédé de prévention et de traitement contre des virus utilisant une lumière bleue
KR20210147847A (ko) 청색광을 이용한 바이러스를 예방 및 치료하는 방법
Chiem et al. Bi-reporter vaccinia virus for tracking viral infections in vitro and in vivo
Teng et al. Possible transmission of Irkut virus from dogs to humans
Ugochukwu et al. Peste des petits ruminants: aetiology, pathology, immunology, disease status in Africa, diagnosis, control, prevention and treatment: a review
Kim et al. Effects of a broad-spectrum caspase inhibitor, Z-VAD (OMe)-FMK, on viral hemorrhagic septicemia virus (VHSV) infection-mediated apoptosis and viral replication
Li et al. Methyltransferase KDKE motif influences the intercellular transmission of Newcastle disease virus
Zeng et al. Infection of goats with goatpox virus triggers host antiviral defense through activation of innate immune signaling
Yu et al. SARS‐CoV‐2 Omicron (B. 1.1. 529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage
Chang et al. Apoptosis induced by bovine ephemeral fever virus
Cheng et al. Development of a SYBR Green I real-time PCR for detection and quantitation of orthopoxvirus by using Ectromelia virus
Lojkić et al. Phylogenetic analysis of bovine herpesvirus 1 isolated in Croatia.
Yang et al. RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation
Faramarzi et al. Epigenetic-related effects of COVID-19 on human cells
Lan et al. Role of autophagy in cellular response to infection with Orf virus Jilin isolate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812862

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21812862

Country of ref document: EP

Kind code of ref document: A1